Distinct and dynamic activation profiles of circulating dendritic cells and monocytes in mild COVID-19 and after yellow fever vaccination
- PMID: 36404054
- DOI: 10.1002/eji.202250090
Distinct and dynamic activation profiles of circulating dendritic cells and monocytes in mild COVID-19 and after yellow fever vaccination
Abstract
Dysregulation of the myeloid cell compartment is a feature of severe disease in hospitalized COVID-19 patients. Here, we investigated the response of circulating dendritic cell (DC) and monocyte subpopulations in SARS-CoV-2 infected outpatients with mild disease and compared it to the response of healthy individuals to yellow fever vaccine virus YF17D as a model of a well-coordinated response to viral infection. In SARS-CoV-2-infected outpatients circulating DCs were persistently reduced for several weeks whereas after YF17D vaccination DC numbers were decreased temporarily and rapidly replenished by increased proliferation until 14 days after vaccination. The majority of COVID-19 outpatients showed high expression of CD86 and PD-L1 in monocytes and DCs early on, resembling the dynamic after YF17D vaccination. In a subgroup of patients, low CD86 and high PD-L1 expression were detected in monocytes and DCs coinciding with symptoms, higher age, and lower lymphocyte counts. This phenotype was similar to that observed in severely ill COVID-19 patients, but less pronounced. Thus, prolonged reduction and dysregulated activation of blood DCs and monocytes were seen in a subgroup of symptomatic non-hospitalized COVID-19 patients while a transient coordinated activation was characteristic for the majority of patients with mild COVID-19 and the response to YF17D vaccination.
Keywords: SARS-CoV-2; YF17D; dendritic cells; monocytes; yellow fever.
© 2022 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.
References
-
- Zhang, J. -J., Dong, X., Liu, G. -H. and Gao, Y. -D., Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality. Clinical Reviews in Allergy & Immunology. 2022. 9: 1-18.
-
- Peyneau, M., Granger, V., Wicky, P. H., Khelifi-Touhami, D., Timsit, J. F., Lescure, F. X., Yazdanpanah, Y. et al., Innate immune deficiencies are associated with severity and poor prognosis in patients with COVID-19. Sci. Rep. 2022. 12(1): 638.
-
- Diamond, M. S. and Kanneganti, T. D., Innate immunity: the first line of defense against SARS-CoV-2. Nat. Immunol. 2022. 23(2): 165-176.
-
- Lim, H. K., Huang, S. X. L., Chen, J., Kerner, G., Gilliaux, O., Bastard, P., Dobbs, K. et al., Severe influenza pneumonitis in children with inherited TLR3 deficiency. J. Exp. Med. 2019. 216(9): 2038-2056.
-
- Galeas-Pena, M., McLaughlin, N. and Pociask, D., The role of the innate immune system on pulmonary infections. Biol. Chem. 2019. 400(4): 443-456.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous